Tirzepatide (GLP-1/GIP)

Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is GLP-1 only. The GIP receptor addition is the key mechanistic difference and is believed responsible for tirzepatide's superior efficacy. In the SURPASS-2 head-to-head trial: tirzepatide 15 mg achieved mean HbA1c reduction of 2.30% vs semaglutide 1 mg at 1.86%; weight loss was 11.2 kg vs 5.7 kg. In SURMOUNT-5 (obesity, not diabetes): 20.2% vs 13.7% weight loss. Note that the semaglutide dose in SURPASS-2 was 1 mg (not the 2 mg diabetes dose or 2.4 mg obesity dose), so these comparisons don't represent maximal semaglutide. The SURMOUNT-5 data using higher semaglutide doses is more informative.

Both contain identical tirzepatide at the same doses (2.5–15 mg weekly SC) but differ in FDA-approved indication. Mounjaro (2022): approved for type 2 diabetes management. Zepbound (2023): approved for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidities, and for obstructive sleep apnea (2024). Insurance coverage differs substantially: T2D patients typically have better Mounjaro coverage; obesity-only patients typically need Zepbound. Physicians may prescribe either for off-label uses, but coverage complications arise.

The GIP (glucose-dependent insulinotropic polypeptide) receptor was historically underestimated because GIP infusion in people with T2D shows minimal insulinotropic effect—suggesting T2D causes GIP receptor downregulation. Tirzepatide appears to restore GIP receptor sensitivity (a 'priming' effect), allowing GIP agonism to contribute significantly once receptor function is re-established. The GIP receptor activates adipocyte receptors to modulate fat storage and release, affects bone density, and may modulate the brain's reward responses to food differently than GLP-1. This multi-mechanism approach explains why dual agonism produces greater weight loss than GLP-1 alone.

SUMMIT (2024; PMID: 39228291) enrolled 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity—a condition with previously limited treatment options. Tirzepatide reduced the composite endpoint of CV death or worsening heart failure by 38% (HR 0.62, 95% CI 0.41–0.95) versus placebo. Participants also showed 15.7% weight loss and significant improvement in 6-minute walk distance and quality of life. HFpEF is strongly associated with obesity and metabolic dysfunction, and this is the first demonstration that treating the underlying obesity significantly improves HFpEF outcomes—potentially establishing a new treatment paradigm.

Active research areas beyond diabetes/obesity include: (1) Obstructive sleep apnea (OSA)—FDA approved in 2024; SURMOUNT-OSA showed 63–73% reduction in apnea-hypopnea index; (2) Non-alcoholic steatohepatitis (NASH/MASH)—SYNERGY-NASH trial showed 74% MASH resolution in biopsied patients; (3) Polycystic ovary syndrome—trials examining effects on PCOS features including hyperandrogenism and cycle regularity; (4) Chronic kidney disease; (5) Alzheimer's disease—GLP-1 receptor is expressed in hippocampus; ongoing EVOKE and similar trials include tirzepatide arms.

Tirzepatide is started at 2.5 mg SC weekly to minimize GI side effects, then increased by 2.5 mg every 4 weeks. The maximum dose is 15 mg weekly for both Mounjaro (T2D) and Zepbound (obesity). The slower titration (4-week steps vs. semaglutide's 4-week steps) reflects similar GI tolerance considerations. Clinical trials show dose-dependent efficacy: 10 mg achieves approximately 19% weight loss, 15 mg approximately 21% weight loss in the SURMOUNT trials. Unlike semaglutide where 2 mg and 2.4 mg are distinct diabetes vs. obesity doses, tirzepatide uses the same doses for both indications.

Tirzepatide's GI side effects (nausea, diarrhea, vomiting, constipation) are similar in type but some analyses suggest modestly higher rates than semaglutide, particularly at the highest doses. Injection site reactions occur in approximately 2–3% of patients. Tirzepatide shares the same class-based contraindications as GLP-1 agonists: MTC/MEN2 family history, pancreatitis history. No new safety signals beyond the established GLP-1 agonist class profile have emerged from the extensive SURPASS/SURMOUNT trials. Long-term cardiovascular outcomes data is pending (SURPASS-CVOT trial); the select GIP receptor mechanism does not raise additional theoretical cardiovascular concerns.

The additional weight loss from dual GIP/GLP-1 agonism (vs. GLP-1 alone) likely involves several synergistic mechanisms: (1) GIP receptors on adipocytes modulate fat storage vs. oxidation differently than GLP-1, and tirzepatide's chronic GIP agonism appears to shift adipocyte function toward reduced fat storage; (2) GIP and GLP-1 target overlapping but distinct hypothalamic circuits—GIP may augment satiety through the infundibular nucleus in ways complementary to GLP-1's arcuate nucleus effects; (3) GIP may improve GLP-1 receptor sensitivity in the brain through heterodimerization; (4) Thermogenic effects via brown adipose tissue GIP receptor activation. The full mechanistic picture remains an active area of research.